Mass. Movers

Cubist agrees to acquire 2 drug makers

Lexington-based Cubist makes Cubicin.

Lexington-based Cubist makes Cubicin.


Cubist Pharmaceuticals Inc., best-known for its antibiotic Cubicin, will pay up to $1.6 billion to acquire two other drug makers in a bid to increase its line of antibiotics. The deal to buy Optimer Pharmaceuticals and Trius Therapeutics adds an antibacterial drug to its product portfolio and puts several other antibiotics in its pipeline for approval. The deals are expected to ultimately generate between $600 million and $1 billion in annual revenue, Cubist CEO Michael Bonney said.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of